🔗 Share this article

An underground market for unapproved weight-loss drugs is being driven by social media fitness personalities and sellers on messaging platforms, according to new investigations.

Investigational Treatment Gaining Popularity Online

Retatrutide, which remains in clinical trials, is being advertised by online personalities for its alleged weight-reducing effects. Followers are urged to message these accounts directly for supplier links, while also receiving promotional offers.

Thriving Commerce on Messaging Platforms

Additionally, a flourishing market exists on messaging services, where communities with thousands of members share comparison images, administration instructions and claims of rapid UK delivery. Vendors market the substance there before redirecting customers to WhatsApp for purchases.

Understanding Retatrutide

This medication is an experimental injection developed by American pharmaceutical company Eli Lilly. The treatment affects three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies suggest it could assist individuals lose up to a quarter of their body weight. Nicknamed the “triple G”, the substance is being hailed online as the successor to Ozempic.

Healthcare Experts Voice Concerns

However, doctors and pharmacists have warned that the sale of what is still an unlicensed drug in the UK is worrisome and could result in users administering products of uncertain source.

Some experts stated the demand for the experimental drug could be connected to the increasing cost of approved weight loss treatments such as Mounjaro.

Regulatory Status and Implementation

Marketing the unapproved drug on social media or Telegram is illegal in the UK, as it is an unapproved medication that must not be promoted or supplied for personal consumption under the British medical regulations.

Some content creators try to circumvent the rules by calling to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled substance, but advertising and supply can still violate medicines, marketing, and consumer regulations, potentially leading to penalties, legal action or prison.

Service Response and Content Elimination

According to the social media company, the platform has taken down problematic content and banned related keywords and query recommendations. The company stated it was dedicated to maintaining the platform safe and allocating resources in enhancing enforcement strategies.

Online Marketplace Activities

Investigations also found groups with up to nine thousand members marketing retatrutide using the platform's built-in discovery tool, which operates like a online catalog. Typing “retatrutide” immediately brings up groups with numerous of users, populated with photos of weight loss, glowing testimonials and step-by-step instructions for preparing or injecting at home.

Within moments of joining one community, a seller shared contact information, where most purchases take place. The vendor sent an instruction manual and promised shipping within 48 hours. When questioned whether the substance was genuine, one seller responded: “You can’t be sure.” Another shared a photo of a alleged laboratory certificate. Not one asked about weight, medical conditions or previous experience.

Item Details and Pricing

Within these communities, posts show black plastic packages with postal service stickers, stating to include fresh supplies. One message stated: “It took eight of us to load them this morning.”

Buyers can select between dry substance containers, prepared at residence with sterile water, or ready-to-use pens typically sold at 160 pounds for 20mg. When asked how long a pen should last, vendors give contradictory responses ranging from a several days to “depends on your body”.

Platform Moderation and Safety Actions

A spokesperson for Telegram stated it regularly moderated harmful content on its service including material that promoted the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.

Medical Expert Cautions

“Individuals are injecting materials they cannot confirm. Although the science behind retatrutide is valid, these digital products may not include what they claim,” said Jason Murphy, the director of pharmaceutical services at Chemist4U.

A medical professional of Asda Online Doctor linked the surge in interest to recent cost increases for approved weight-loss medications such as Mounjaro. “With costs rising, patients are using online platforms. But counterfeit injections are extremely dangerous. You can’t be certain what’s contained or whether the conditions they were produced in was sterile,” she explained.

Her staff has already seen individuals injured by self-injection from unverified sources. “We recognize the frustration, but buying from Telegram or communication platforms is gambling with your well-being,” said the doctor. “These substances could be contaminated or improperly measured.”

Producer Statement

A representative from Eli Lilly stated retatrutide was in phase 3 research studies and had not been evaluated or approved by any government authority globally. “Therefore at this time no one can market [it] for personal consumption,” they said, noting that any item “misleadingly claiming itself as a Lilly experimental product not yet authorized … may expose users to possibly significant health risks”.